DOCSLIB.ORG

IHH Healthcare UNDERPERFORM ↔ Price: RM5.60 3QFY20 Recovers, India Still Loss-Making Target Price: RM4.56 ↔ by Raymond Choo Ping Khoon L [email protected]

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
IHH Healthcare UNDERPERFORM ↔ Price: RM5.60 3QFY20 Recovers, India Still Loss-Making Target Price: RM4.56 ↔ by Raymond Choo Ping Khoon L Pkchoo@Kenanga.Com.My Results Note 27 November 2020 IHH Healthcare UNDERPERFORM ↔ Price: RM5.60 3QFY20 Recovers, India Still Loss-making Target Price: RM4.56 ↔ By Raymond Choo Ping Khoon l [email protected] 9MFY20 Core Net Profit (CNP) of RM344m (-46% YoY) came Share Price Performance in at 53%/62% of our/consensus full-year forecasts. We consider the results to be within our expectation in 6.10 anticipation of further earnings recovery following strong 5.90 rebound in occupancy rates on the back of the gradual 5.70 reopening of markets which IHH operates in. Looking at the 5.50 performance of its 62%-owned Continental Hospitals and 5.30 74%-owned Global Hospitals acquired back in 2015 where 5.10 its EBITDA is hardly ever positive, India is coming across 4.90 as a tough market place. We maintain our SoP-TP of 4.70 RM4.56. Reiterate UP. 4.50 Key results’ highlights. QoQ, 3QFY20 headline revenue and EBITDA KLCI 1,612.11 rebounded from a low base in 2QFY20 by 37% and 210%, respectively, YTD KLCI chg 1.5% due to rebound in occupancy rates following easing of travel restrictions YTD stock price chg 2.4% and lockdowns. Specifically, Turkey showed a strong recovery as lockdowns eased markedly. Similarly, EBITDA increased across the Stock Information board led by strong rebound in inpatient admissions. Overall inpatient Shariah Compliant Yes admission rose across the board including Singapore (+26%), Malaysia Bloomberg Ticker IHH MK Equity (+37%), India (+37%) and Acibadem (+27%). This brings 3QFY20 Core Market Cap (RM m) 49,152.4 Net Profit (CNP) to RM234m compared to a core net loss of RM84m Shares Outstanding 8,777.2 2QFY20 due to narrower losses at India (3QFY20 core net loss at 52-week range (H) 5.94 RM28m compared to 2QFY20 of RM156m). 52-week range (L) 4.55 YoY, 9MFY20 revenue and EBITDA decreased 13% and 24%, 3-mth avg daily vol: 2,636,431 respectively, due to the pandemic as patients postponed non-urgent Free Float 11% and non-essential treatment and visits to hospitals and healthcare Beta 0.8 facilities (primarily in 2QFY20). The Group also saw a decrease in foreign patient volume especially from March 2020 onwards due to the Major Shareholders various travel restrictions implemented across the countries that it Mitsui & Co Ltd 32.9% operates in. Overall, inpatient admission fell across the board including PulauMemutik Ven SdnBhd 26.0% Singapore (-21%), Malaysia (-25%), India (-28%) and Acibadem (- Employees Provident Fund 9.7% 17%). This brings 9MFY20 CNP to RM344m (-46%) (excluding an impairment on the remaining goodwill of RM400.5m from an investment Summary Earnings Table made into Global Hospitals in India) due to widening losses in India. FY Dec (RMm) 2019A 2020E 2021E Outlook. The group has undertaken cost initiatives measures to defer Turnover 14,913 11,909 15,030 non-essential capex and opex to mitigate any revenue shortfall. The PBT 1,047.7 847.1 1,527.3 Group took pro-active initiatives to partially mitigate the effects of lower Net Profit (NP) 556.5 649.5 929.7 patient volumes by improving case-mix and diversifying into new Core NP 920.7 649.5 929.7 revenue streams by providing COVID-19 screening services. COVID-19 Consensus (NP) 550.6 977.7 related services contributed about 10%, 3% and 21% of the 3QFY20 Earnings Revision - - - revenues in Singapore, Turkey and India, respectively. The Group has Core EPS (sen) 10.5 7.4 10.6 also entered into an agreement to dispose its 50% interest in Apollo Core EPS growth (%) (10.5) (29.5) 43.1 Gleneagles Hospital Limited, a joint venture, and the disposal is NDPS (sen) 4.0 4.0 4.0 expected to be completed by 15 December 2020.Thus far, the group BVPS (RM) 2.55 2.58 2.65 has further deleveraged its non-lira debt in its Turkish operations from Core PER (x) 51.6 78.2 54.7 EUR288m as at Dec 2019 to EUR92m as at Sept 2020. Looking at the PBV(x) 2.2 2.2 2.1 Net Gearing (%) 18.8 26.4 22.1 performance in 62%-owned Continental Hospitals and 74%-owned Net Div. Yield (%) 0.7 0.7 0.7 Global Hospitals acquired back in 2015 where EBITDA is hardly positive, India is seen as a tough operating environment. We are concerned over issues at Fortis, including an auditor’s qualified audit report in FY19, potential risk of provisions, lapses in internal controls leading to regulatory probing, which could well mean execution risk. Maintain UP. We maintain our SoP-TP of RM4.56. The stock is trading at rich valuations of 78x and 54x on FY20E and FY21E EPS, respectively, compared to expected earnings growth averaging 7% each over the next two years. Key risk to our call is faster-than-expected ramp-up in new hospitals. PP7004/02/2013(031762) Page 1 of 5 IHH Healthcare Results Note 27 November 2020 Result Highlight (YTD) FY Dec 2019 2020 Y-o-Y (RM m) 9M 9M Chg (%) Turnover 11,076.4 9,638.6 (13.0) Parkway Pantai 8,001.0 6,841.4 (14.5) Acibadem Holdings 2,776.2 2,492.3 (10.2) IMU Health 192.5 184.6 (4.1) Plife REIT 259.7 274.8 5.8 Others (Plife REIT inter-segment revenue) (153.0) (154.4) 0.9 EBITDA 2,416.2 1,834.7 (24.1) Parkway Pantai 1,740.5 1,261.8 (27.5) Acibadem Holdings 606.7 515.8 (15.0) IMU Health 73.7 63.2 (14.2) Plife REIT 211.3 217.3 2.8 Others (59.7) (64.9) 8.7 Eliminations (156.3) (158.6) 1.5 Depreciation & amortisation (959.7) (1,004.5) 4.7 Other operating income 232.3 559.9 141.0 Finance cost (658.4) (881.6) 33.9 Finance income 101.2 243.8 140.9 Associates and JV (15.1) 3.6 (124.1) Pretax profit 847.0 (93.4) (111.0) Taxation (372.2) (196.2) (47.3) Minority interest 36.0 159.1 341.8 PATAMI 510.8 (130.5) (125.5) Core net profit 630.8 343.6 (46) Core EPS (sen) 6.4 3.2 (51) EPS (sen) 5.1 (2.3) (144.5) EBITDA margin (%) 22 19 Parkway Pantai 22 18 Acibadem Holdings 22 21 IMU Health 38 34 Pretax margin (%) 8 (1) Effective tax rate (%) 44 (210) Source : Bursa Malaysia, Kenanga Research PP7004/02/2013(031762) Page 2 of 5 IHH Healthcare Results Note 27 November 2020 Result Highlight FY Dec 1Q 2Q 3Q QoQ (RMm) 2020 2020 2020 %chg Turnover 3,555.2 2,565.1 3,518.3 37.2 Parkway Pantai 2,492.6 1,847.0 2,501.8 35.5 Acibadem Holdings 955.8 613.9 922.7 50.3 IMU Health 67.3 63.2 54.0 (14.5) PLife REIT 90.0 92.5 92.2 (0.3) Others (Plife REIT inter-segment revenue) (50.5) (51.5) (52.4) 1.8 EBITDA 734.4 268.0 832.7 210.7 Parkway Pantai 486.6 178.5 596.7 234.3 Acibadem Holdings 217.3 74.5 224.1 201.0 IMU Health 28.5 22.8 12.0 (47.5) PLife REIT 70.4 73.7 73.6 (0.2) Others (16.1) (28.4) (20.4) (28.3) Eliminations (52.3) (53.0) (53.3) 0.4 Depreciation & amortisation (324.2) (325.4) (354.9) 9.1 Other operating income 105.6 158.5 295.8 86.6 Finance cost^ (288.6) (217.4) (375.6) 72.8 Finance income^ 72.7 58.2 112.9 94.0 Associates and JV 1.6 (3.6) 5.6 (257.6) Pretax profit (257.4) (232.0) 396.0 (270.7) Taxation (109.3) (0.1) (86.8) NM Minority interest 46.9 111.5 0.8 (99.3) Net profit (319.8) (120.6) 310.0 (356.9) EPS (sen) (3.9) (1.6) 3.3 (300.0) Core net profit 189.4 (84.2) 238.4 NM EBITDA margin (%) 21 10 24 Parkway Pantai 20 10 24 Acibadem Holdings 23 12 24 IMU Health 42 36 22 Pretax margin (%) (7) (9) 11 Effective tax rate (%) (42) (0) 22 Source : Bursa Malaysia, Kenanga Research Sum-of-parts valuation Basis Multiples (x) Value (RM m) Remarks PPL EV/EBITDA 17.00 29,511 17x which is inline with peers average. Acibadem (60%) EV/EBITDA 16.00 11,434 16x due to uncertain Turkey Lira Fortis (31.1%) Market value 341 Market value IMU EV/EBITDA 11.00 638 Premium to peers due to higher earnings base. International EV/EBITDA 11.00 2,700 In line with peers average. Plife REIT (35.8%) 1,461 Total 46,086 Net debt (6,136) Total 39,949 No of shares (m) 8,769 Target price (RM) 4.56 Source: Kenanga Research PP7004/02/2013(031762) Page 3 of 5 IHH Healthcare Results Note 27 November 2020 Peer Comparison Net Revenue Core Earnings ROE Name Market PER (x) - Core Earnings PBV (x) DivYld Target Last Price Current Growth Growth (%) Cap Shariah (%) Price Rating (RM) Compliant FYE (RM'm) 1-Yr. 2-Yr. 1-Yr. 2-Yr. 1-Yr. 2-Yr. 1-Yr. 1-Yr. 1-Yr. (RM) Hist. Hist. Fwd. Fwd. Fwd. Fwd. Fwd. Fwd. Fwd. Fwd. Fwd. HEALTHCARE IHH HEALTHCARE BHD 5.60 49,152 Y 12/2020 -20% 26.7% -30% 43.0% 50.1 75.6 52.8 2.1 2.2 2.9% 0.7% 4.56 UP KPJ HEALTHCARE BERHAD 0.905 3,873 Y 12/2020 -8.7% 5.8% -32% 15.9% 18.8 27.5 23.7 2.1 2.0 7.5% 2.2% 1.00 OP PHARMANIAGA BERHAD 5.57 1,458 Y 12/2020 -2.4% -2.7% 34.6% -4.0% 32.2 23.9 24.9 4.3 3.9 17.1% 2.2% 1.80 UP Source: Bloomberg, Kenanga Research The rest of the page is intentionally left blank PP7004/02/2013(031762) Page 4 of 5 IHH Healthcare Results Note 27 November 2020 Stock Ratings are defined as follows: Stock Recommendations OUTPERFORM : A particular stock’s Expected Total Return is MORE than 10% MARKET PERFORM : A particular stock’s Expected Total Return is WITHIN the range of -5% to 10% UNDERPERFORM : A particular stock’s Expected Total Return is LESS than -5% Sector Recommendations*** OVERWEIGHT : A particular sector’s Expected Total Return is MORE than 10% NEUTRAL : A particular sector’s Expected Total Return is WITHIN the range of -5% to 10% UNDERWEIGHT : A particular sector’s Expected Total Return is LESS than -5% ***Sector recommendations are defined based on market capitalisation weighted average expected total return for stocks under our coverage.
Load more

Recommended publications
  • Healthcare Business Strategy Healthcare & Service Business Unit Koji Nagatomi
    Healthcare Business Strategy Healthcare & Service Business Unit Koji Nagatomi Copyright © MITSUI & CO., LTD. ALL RIGHTS RESERVED. Healthcare Market in Asia Growth of Asia’s* healthcare spending Accelerating growth *South East Asia + China + India （USD bil） unaffected by economic 3,100 conditions Changes in Population Income Aging Disease 710 Growth Growth Population Patterns 2016 2030 (Source) OECD, World Bank, Mitsui’s forecasts Copyright © MITSUI & CO., LTD. ALL RIGHTS RESERVED. 2 Healthcare Market in Asia Significant shortage of Number of hospital beds per 1,000 population （Number of beds） hospitals 4.8 (no. of beds) 2.8 2.8 2.3 1.9 Changes in 0.7 Population Income Aging Disease Growth Growth Population Patterns OECD Singapore Malaysia India China Turkey Average （Source） METI, Government of Singapore, World Bank, OECD Copyright © MITSUI & CO., LTD. ALL RIGHTS RESERVED. 3 Hospital Business Management in Asia Increased volume and quality of care Maximized value of medical services Management Structure Challenge／Lever ① Challenge／Lever ② Challenge／Lever ③ Increasing Revenue M&A・Increasing (unit price x no. Optimizing Cost No. of Beds of patients) Strategic problem solving from a management perspective Doctors Patients Problems can be solved utilizing business knowhow Trust and expectations Copyright © MITSUI & CO., LTD. ALL RIGHTS RESERVED. 4 Mitsui’s Resources in Hospital Business ■Progress in management participation and expansion of human resources Additional (Persons) Additional investment in IHH Investment in investment in Platform 60 ■Industry experts（MHM） Columbia Asia Columbia Asia Developing a large and strong platform ■ 50 MBK staff seconded DaVita and PHC 5 by participating in management of ■MBK staff at HQ 1 hospital businesses, such as IHH.
    [Show full text]
  • News Release MAYBANK INVESTMENT BANK
    News Release MAYBANK INVESTMENT BANK AFFIRMS LEADERSHIP POSITION BY GARNERING SEVERAL MORE PRESTIGIOUS AWARDS - Maybank Investment Bank was named Best Debt House and was awarded the Best Islamic Equity, Best Local Currency Sukuk, Best Islamic Project Finance and Highly Commended Best Islamic Equity for its role in major deals. - Its analyst was recognised as Malaysia’s best. - Its offices in the Philippines, Thailand and Vietnam also netted the Best Retail Broker and Best Institutional Broker awards. Kuala Lumpur, 3 July 2013 – After clinching an array of awards from the 10th RAM Rating Services League Awards earlier this year, it appears that Maybank Investment Bank (“Maybank IB”) has more awards to add to its list of accomplishments. At the Asiamoney awards, Maybank IB was named the Best Debt House for 2013. The award was given based on internal research and recommendations from industry experts such as analysts and fund managers. Last year, Maybank IB’s Debt House had 37 Malaysian Ringgit (“RM”) denominated bond deals consisting of 176 issuances with a total deal value of RM23,396.20 million. It also holds a commanding 26.7% market share of the Malaysian bond market and a market-leading 29.4% market share of the Malaysian sukuk market for the period under review. By being client-focused and solutions-driven, Maybank IB was able to deliver unique debt solutions that pushed innovative boundaries and further deepened and broadened the Malaysian bond and sukuk market. Page 1 of 5 Among the many landmark transactions which Maybank IB had
    [Show full text]
  • Market Cap Gap Between Top Glove and Maybank Narrows to RM8
    Headline Market cap gap between Top Glove and Maybank narrows to RM8 bil MediaTitle The Edge Date 28 Sep 2020 Language English Circulation 25,910 Readership 77,730 Section Corporate Page No 20,24 ArticleSize 606 cm² Journalist ARJUNA CHANDRAN PR Value RM 31,543 Market cap gap between Top Glove and Maybank narrows to RM8 bil BLOOMBERG BLOOMBERG BY ARJUNA CHANDRAN SHANKAR Market caps of top 10 KLCI component stocks Selldown in banking stocks (as at Sept 25) he market capitalisation of Market cap (RM bil) Malayan Banking Bhd has LAST PRICE (RM) P/B (TIMES) YTD CHANGE (%) Malayan Banking 79.59 NAME shrunk to below RM80 bil- AFFIN Bank 1.40 0.29 -26.3 lion, as the selldown of bank- Top Glove Corp Alliance Bank Malaysia 2.18 0.56 -17.1 ing stocks continued, further Tenaga Nasional -24.8 reducing the gap between the most AMMB Holdings 2.94 0.46 T Public Bank valuable company on the local stock BIMB Holdings 3.45 0.97 -21.6 Hartalega Holdings exchange and the next in line, Top CIMB Group Holdings 3.06 0.54 -40.6 IHH Healthcare Glove Corp Bhd. Maybank declined Hong Leong Bank 14.84 1.12 -14.2 0.14%, or one sen, to RM7.08 last Fri- Petronas Chemicals Group Hong Leong Financial Group 13.80 0.75 -18.3 day, valuing it at RM79.59 billion. A Maxis 0.97 -18.1 total of 4.51 million shares were trans- Malayan Banking 7.08 acted. On a year-to-date basis, the Sime Darby Plantation Public Bank 15,44 1.34 -20.6 counter has declined 18.1% (see table).
    [Show full text]
  • IHH Healthcare
    8 May 2018 Company Update HLIB Research PP 9484/12/2012 (031413) IHH Healthcare Sheikh Abdullah [email protected] Like a Bollywood feature film (603) 2083 1711 nd IHH has made several revised offers for a stake in Fortis (India’s 2 largest hospital chain). Its newly revised offer encompasses a binding (INR650 Crore) HOLD (Maintain) and non-binding (INR3350 Crore) portion at a price not exceeding INR175/share. This effectively values Fortis at 24x EV/EBITDA compared to IHH’s 19.4x Target Price: RM6.07 (FY18).We expect this offer will trigger a GO and net gearing to increase to Previously: RM6.07 0.14x-0.4x. Maintain Hold and a TP of RM6.07. Current Price: RM5.96 Capital upside 1.8% The proposal. Over the course of the past few weeks, IHH has made several revised Dividend yield 0.6% offers to the board of Fortis Healthcare expressing its interest in “participating in Fortis Expected total return 2.4% and its affiliates”. IHH’s initial non-binding offer was for INR4000 Crore (c.RM2.4bn) in totality for an equity portion of Fortis via a preferential issue and allotment of equity Sector coverage: Healthcare shares at INR160/share (c.RM9.42). This equity injection is for the immediate liquidity Company description: IHH runs a chain of requirements for working capital, short term funding requirement, the RHT (Religare hospitals in Malaysia, Singapore, Turkey, India and Healthcare Trust) buyout and infrastructure work. The offer price has since been China. revised however we understand that IHH’s absolute total value of the investment (INR4000 Crore) is fixed.
    [Show full text]
  • Public Mutual Bhd Has Declared a Gross Distribution of 1
    Press Release 31 July 2012 AmBank Issues Six New Call Warrants AmBank (M) Berhad (“AmBank”) is issuing six new European style cash-settled structured call warrants (“CW”) over the ordinary shares of IHH Healthcare Berhad (“IHH”) to meet investors’ demand for trading and investment opportunities in the current market scenario. The structured warrants will be listed for trading on 1 August 2012, via the market making method, with issue size of up to 100 million each. “Healthcare group IHH posted strong gains on its maiden day of trading on Bursa Malaysia, closing up 10.4% at RM3.09 after trading as high as RM3.19 earlier in the day. IHH’s IPO was much anticipated as evidenced by the overwhelming institutional demand for its shares, which was oversubscribed by more than 100 times with a record 22 cornerstone investors. IHH’s listing is also the first concurrent offering on both the Main Market of Bursa Malaysia and the Main Board of Singapore Exchange, enabling the group to tap a wider investor base in both Malaysia and Singapore. On the back of IHH’s strong debut, AmBank is issuing six call warrants on IHH, with varying exercise prices and ratios. This is to cater to investors’ demand for alternatives to participate in IHH’s stock performance over the coming months,” said Ms Ng Ee Fang, Director/Head, Equity Derivatives, AmInvestment Bank Berhad. IHH is the second largest listed healthcare group in the world in terms of market capitalisation. Currently it has a global network of 30 hospitals under various premium brands such as Parkway, Pantai and Gleneagles.
    [Show full text]
  • Lesser Government in Business: an Unfulfilled Promise? by Wan Saiful Wan Jan Policy Brief NO
    Brief IDEAS No.2 April 2016 Lesser Government in Business: An Unfulfilled Promise? By Wan Saiful Wan Jan Policy Brief NO. 2 Executive Summary Introduction This paper briefly outlines the promise made by Reducing the Government’s role in business has the Malaysian Government to reduce its role in been on Prime Minister Dato’ Sri Najib Tun business as stated in the Economic Transformation Razak’s agenda since March 2010, when he Programme (ETP). It presents a general argument launched the New Economic Model (NEM). The of why the Government should not be involved NEM called for a reduction in Government in business. It then examines the progress intervention in the economy and an increase made by the Government to reduce its role in economic liberalisation efforts. The NEM in business through data showing Government furthermore, acknowledged that private sector divestments in several listed companies. growth in Malaysia has been hampered by “heavy Government and GLC presence” and This paper then demonstrates how this progress is offset by two factors – (i) the increased shares of Government-Linked Companies that there is a serious need to “reduce direct (GLCs) in the Kuala Lumpur Composite Index (KLCI) and (ii) the state participation in the economy” (National higher amount of combined GLC and GLIC asset acquisitions as opposed to asset disposals. This paper concludes with the argument Economic Advisory Council (NEAC), 2009). that the Government has not fulfilled its promise but in fact, has done the exact opposite. The increased shares of Government- 01 Linked Companies (GLCs) in the Kuala Author Two Factors Lumpur Composite Index (KLCI).
    [Show full text]
  • Hong Leong Bank Berhad
    November 13, 2020 Global Markets Research Fixed Income Fixed Income Dail y Market Snapshot US Treasuries US treasuries reopened Thursday on a bid tone as purported lockdown news amid continuous surge in coronavirus cases sent chills to the UST markets. The sell-off in equities prompted flight to safety into UST, bull Tenure Closing (%) Chg (bps) flattening the curve with the short end 2s ended little changed at 0.17% 2-yr UST 0.17 0 while the 10s saw yields being pushed 9bps lower at 0.88%, its lowest 5-yr UST 0.39 -6 in four days. The 2/10 spread widened to 71bps (from 80bps) while the 10-yr UST 0.88 -9 5/30 to 125bps (from 130bps). Yesterday’s 30Y bond auction was sold 30-yr UST 1.64 -10 at a high yield of 1.68% (prior 1.578%) with a BTC of 2.29x. Expect headlines on Covid-19 pandemic and vaccine to be the prime market MGS GII* mover, amid intermittent noises from the US presidential transition with Closing Tenure Closing (%) Chg (bps) Chg (bps) President Trump still in denial of a defeat. Tonight’s PPI and University (%) of Michigan consumer sentiments will unlikely have a significant 3-yr 1.81 0 1.92 0 bearing on the UST markets. Inflation is heading no way as reaffirmed 5-yr 2.14 0 2.29 4 by the softer than expected CPI print overnight. 7-yr 2.42 0 2.41 6 10-yr 2.68 1 2.61 0 15-yr 3.04 -3 3.14 0 MGS/GIIl 20-yr 3.40 0 3.51 0 Local govvies saw another day of subdued trading amid ongoing jitters 30-yr 4.01 15 4.06 0 surrounding the approval of the national budget and anxiety ahead of * Market indicative levels the release of 3Q GDP, due today.
    [Show full text]
  • FTSE Publications
    2 FTSE Russell Publications 28 October 2020 FTSE Malaysia Indicative Index Weight Data as at Closing on 27 October 2020 Constituent Index weight (%) Country Constituent Index weight (%) Country Constituent Index weight (%) Country AirAsia Group Berhad 0.16 MALAYSIA Hong Leong Bank 1.83 MALAYSIA Press Metal Aluminium Holdings 2.07 MALAYSIA Alliance Bank Malaysia 0.48 MALAYSIA Hong Leong Financial 0.66 MALAYSIA Public Bank BHD 9.5 MALAYSIA AMMB Holdings 1.1 MALAYSIA IHH Healthcare 2.99 MALAYSIA QL Resources 1.31 MALAYSIA Astro Malaysia Holdings 0.22 MALAYSIA IJM 0.87 MALAYSIA RHB Bank 1.3 MALAYSIA Axiata Group Bhd 2.49 MALAYSIA IOI 2.73 MALAYSIA Sime Darby 1.65 MALAYSIA British American Tobacco (Malaysia) 0.27 MALAYSIA IOI Properties Group 0.31 MALAYSIA Sime Darby Plantation 3.39 MALAYSIA CIMB Group Holdings 4.14 MALAYSIA Kuala Lumpur Kepong 2.05 MALAYSIA Sime Darby Property 0.38 MALAYSIA Dialog Group 3.3 MALAYSIA Malayan Banking 8.28 MALAYSIA Telekom Malaysia 0.93 MALAYSIA Digi.com 2.8 MALAYSIA Malaysia Airports 0.74 MALAYSIA Tenaga Nasional 7.53 MALAYSIA FGV Holdings 0.41 MALAYSIA Maxis Bhd 2.65 MALAYSIA Top Glove Corp 8.82 MALAYSIA Fraser & Neave Holdings 0.64 MALAYSIA MISC 1.9 MALAYSIA Westports Holdings 0.8 MALAYSIA Gamuda 1.48 MALAYSIA Nestle (Malaysia) 1.69 MALAYSIA YTL Corp 0.72 MALAYSIA Genting 1.34 MALAYSIA PETRONAS Chemicals Group Bhd 3.28 MALAYSIA Genting Malaysia BHD 1.11 MALAYSIA Petronas Dagangan 1.18 MALAYSIA Hap Seng Consolidated 0.93 MALAYSIA Petronas Gas 1.79 MALAYSIA Hartalega Holdings Bhd 5.25 MALAYSIA PPB Group 2.49 MALAYSIA Source: FTSE Russell 1 of 2 28 October 2020 Data Explanation Weights Weights data is indicative, as values have been rounded up or down to two decimal points.
    [Show full text]
  • ESG Ratings of Plcs Assessed by FTSE Russell# in Accordance with FTSE Russell ESG Ratings Methodology
    ESG Ratings of PLCs assessed by FTSE Russell# in accordance with FTSE Russell ESG Ratings Methodology Definition Top 25% by ESG Ratings amongst PLCs in FBM EMAS that have been assessed by FTSE Russell Top 26-50% by ESG Ratings amongst PLCs in FBM EMAS that have been assessed by FTSE Russell Top 51%- 75% by ESG Ratings amongst PLCs in FBM EMAS that have been assessed by FTSE Russell Bottom 25% by ESG Ratings amongst PLCs in FBM EMAS that have been assessed by FTSE Russell Stock Company Name Sector F4GBM ESG Grading Code (sorted By Alphabetical) Index Band 6599 AEON CO. (M) BHD CONSUMER PRODUCTS & SERVICES ** 5139 AEON CREDIT SERVICE (M) BHD FINANCIAL SERVICES Yes *** 7078 AHMAD ZAKI RESOURCES BHD CONSTRUCTION *** 5099 AIRASIA GROUP BERHAD CONSUMER PRODUCTS & SERVICES *** 5238 AIRASIA X BERHAD CONSUMER PRODUCTS & SERVICES ** 2658 AJINOMOTO (M) BHD CONSUMER PRODUCTS & SERVICES Yes *** 2488 ALLIANCE BANK MALAYSIA BERHAD FINANCIAL SERVICES Yes *** 5293 AME ELITE CONSORTIUM BERHAD CONSTRUCTION * 1015 AMMB HOLDINGS BHD FINANCIAL SERVICES Yes **** 6556 ANN JOO RESOURCES BHD INDUSTRIAL PRODUCTS & SERVICES * 6399 ASTRO MALAYSIA HOLDINGS BERHAD TELECOMMUNICATIONS & MEDIA Yes **** 6888 AXIATA GROUP BERHAD TELECOMMUNICATIONS & MEDIA Yes *** 5106 AXIS REITS REAL ESTATE INVESTMENT TRUSTS ** 3395 BERJAYA CORPORATION BHD INDUSTRIAL PRODUCTS & SERVICES ** 1562 BERJAYA SPORTS TOTO BHD CONSUMER PRODUCTS & SERVICES ** 5248 BERMAZ AUTO BERHAD CONSUMER PRODUCTS & SERVICES Yes **** 2771 BOUSTEAD HOLDINGS BHD INDUSTRIAL PRODUCTS & SERVICES ** 4162 BRITISH AMERICAN
    [Show full text]
  • Download Chapter 2
    28 Key Highlights 2019 29 Overview 29 C&M Industry Market Performance 33 C&M Industry Financial Performance 34 Telecommunications Sector 40 Broadcasting Sector 41 Postal and Courier Sector 42 ACE Market Overview and Performance This chapter reports on the economic performance of the C&M industry, mainly on the market capitalisation including Bursa Malaysia market capitalisation by sector; telecommunications, broadcasting, postal and courier. This chapter also analyses the financial performance including industry revenue by sector, capital expenditure and ARPU. In addition, it also provides an overview and performance of the ACE Market. KEY HIGHLIGHTS 2019 28 INDUSTRY PERFORMANCE REPORT 2019 OVERVIEW DOMESTIC GROWTH The C&M industry market capitalisation remained resilient despite the external headwinds and global SOFTENED IN 2019, WITH economic uncertainties and continued to play a vital role in contributing to the domestic economy. MIXED PERFORMANCES Sector-wide cost rationalisation continues to ACROSS COMMUNICATIONS be at the forefront of the C&M industry players’ initiatives against the persistent and increasing stiff AND MULTIMEDIA (C&M) competitiveness in the market. INDUSTRY C&M INDUSTRY MARKET PERFORMANCE The C&M industry represents 8.4% or RM144.01 billion of Bursa Malaysia total market capitalisation of RM1,711.84 billion as at end 2019 (2018: 8.1% C&M Industry or RM137.73 billion). The C&M industry market capitalisation has increased by 4.6%, spurred Market Capitalisation by telecommunications sector. This is due to RM144.01 telecommunication companies’ share prices gaining billion 4.6% momentum, driven by corporate announcements (2018: RM137.73 billion) such as 5G initiatives, new product launch, collaborations and financial results.
    [Show full text]
  • Stay Defensive on Expectation of More Pressure on Stocks
    Headline Stay defensive on expectation of more pressure on stocks MediaTitle The Edge Date 04 May 2020 Language English Circulation 25,910 Readership 77,730 Section Corporate Page No 22,23 ArticleSize 1300 cm² Journalist N/A PR Value RM 67,149 Stay defensive on expectation of more pressure on stocks T*P hpnrhmark index FTSE Bursa Malaysia KLCI has rebounded since March 19, but analysts say there could ^sSnoS^Shrust. With the uncertainty over Covid-19 and how the worlds economy, respond post- pandemic, what should investors do when it comes to investing in the local stock market. BY KAMARUL AZHAR t has been a tumultuous four months for Malaysian equities, and analysts warn of further volatility ahead as a possible recession looms, caused by the Move- ment Control Order (MCO) and cautious consumer sentiment. Investors are ad- vised to stay defensive and invest in stocks that have defensive earnings qualities and strong fundamentals. Imran Yusof, senior analyst at MIDF Research,believes the FBM KLCI will face some downward pressure, given that sen- timent is likely to be hit by weak econom- ic data and corporate earnings, which are scheduled for release in the next couple of months following nearly two months of economic stagnation. "Therefore, there might be another downward thrust in the direction of the FBM KLCI. In addition, a bear market gen- erally follows a three-wave pattern, where- by the downward thrust (which we saw in March) would normally be interrupted by -19) at a department store in Seoul, South Korea April 30, 2020. an intermittent rebound and subsequent- People wear masks to avoid the spread of the coronavirus disease (COVID ly followed by another downward thrust," Imran tells The Edge via email.
    [Show full text]
  • IHH Healthcare Invests in Genomic Medicine Company to Provide Cancer Patients Better Treatment Outcomes
    FOR IMMEDIATE RELEASE Kuala Lumpur/ Singapore, 20 November 2019 IHH Healthcare Invests In Genomic Medicine Company to Provide Cancer Patients Better Treatment Outcomes • Led minority investment in genomic medicine start-up Lucence • Offers patients clinically validated blood-based cancer screening and treatment monitoring solutions with a focus on cancers commonly found in Asia • Embraces value-based healthcare approach that aims to improve clinical outcomes through less invasive, more precise, and more affordable technology IHH Healthcare (“IHH” or the “Group”), a leading premium global healthcare provider, led a minority investment in Singapore-based genomic medicine company Lucence as part of a USD $20 million Series A. The investment is part of IHH’s collaboration with start-ups to deploy innovative and cutting-edge healthcare technology to enhance the patient experience, treatment and clinical outcomes across its network of 80 hospitals in 10 countries. In Singapore, for example, IHH is working with a local start-up to improve estimated bill size for patients ahead of admission through predictive AI. The partnership with Lucence will give IHH patients access to Lucence’s suite of cancer diagnostics and AI- driven analytics. Lucence uses liquid biopsy, a blood-based technology that is less invasive than tissue biopsies, to help clinicians discover a range of information about a tumour and aid in their treatment decisions through a simple blood sample. It focuses on Asia-prevalent cancers such as lung, breast, colorectal, pancreatic, nasopharyngeal and liver cancers. Dr Kelvin Loh, Chief Executive Officer (Designate) of IHH Healthcare, said, “Liquid biopsy is a game- changer in our endeavour to provide cancer patients with better, value-driven outcomes through precise treatment selections and more affordable care.
    [Show full text]